SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB


 [x]     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934.

                  For the quarterly period ended April 30, 1998

                                       OR

 [ ]     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         ACT OF 1934.

                  For the transition period from          to         
                                                 --------    --------

                         Commission file number 2-86360



                                INFORMEDICS, INC.
         (Exact name of small business issuer as specified in its charter)

          Oregon                                       93-0750571
 (State of incorporation)                  (I.R.S. Employer Identification No.)



        4000 Kruse Way Place, Bldg 3, Suite 300, Lake Oswego, OR  97035
                     (Address of principal executive offices)

                    Issuer's telephone number: (503) 697-3000

Check  whether  the issuer  (1) has filed all  reports  required  to be filed by
Section 13 or 15(d) of the Securities  Exchange Act of 1934 during the preceding
12 months (or for such shorter  period that the issuer was required to file such
reports),  and (2) has been subject to such filing  requirements for the past 90
days. Yes X No

Number of shares of Informedics, Inc. $.01 par value common stock outstanding
as of May 31, 1998:  2,674,502.



<PAGE>




                                INFORMEDICS, INC.


                         Part I - Financial Information




          The   information   included  herein  is  unaudited.   However,   such
 information  reflects all adjustments  (consisting solely of normal,  recurring
 adjustments)  which are, in the  opinion of  management,  necessary  for a fair
 presentation of the results of operations for the interim periods.  The interim
 financial  information and notes thereto should be read in conjunction with the
 Company's  latest annual report on Form 10-KSB.  The results of operations  for
 the six months ended April 30, 1998 are not  necessarily  indicative of results
 to be expected for the entire year.

                                       2

<PAGE>


INFORMEDICS,  INC.
STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>

                                             Three Months Ended April 30,                    Six Months Ended April 30,
                                         -----------------------------------------     ---------------------------------------
                                                1998                  1997                    1998                 1997

                                         ------------------    -------------------     -------------------   -----------------
<S>                                             <C>                  <C>                    <C>                  <C>   
REVENUE:
Product Sales                                   $  46,175             $  274,249             $  208,836           $  424,010
Customer Service and Support                      647,924                640,985              1,289,033            1,336,920
                                         ------------------    -------------------    -------------------    -----------------

Total Revenue                                     694,099                915,234              1,497,869            1,760,930
                                         ------------------    -------------------     ------------------    -----------------

COSTS AND EXPENSES:
Cost of Products Sold                              15,180                 25,450                 52,305               53,661
Cost of Customer Service and Support
                                                  293,169                471,916                527,444              973,002
Selling & Administrative Expenses                 198,386                521,721                473,887            1,006,868
Depreciation & Amortization                        20,379                100,627                 81,396              202,237
                                         ------------------    -------------------     ------------------    -----------------

Total Costs and Expenses                          527,114              1,119,714              1,135,032            2,235,768
                                         ------------------    -------------------     ------------------    -----------------

Operating Profit                                  166,985               (204,480)               362,837             (474,838)
(Loss)
                                         ------------------    -------------------     ------------------    -----------------

OTHER INCOME (EXPENSE):
Interest Expense                                      ---                   (686)                  (832)              (4,521)
Interest Income                                    18,594                 11,019                 21,919               19,699
Other Income                                       17,471                  6,430                 24,751               10,099
                                         ------------------    -------------------     ------------------    -----------------

Total Other Income                                 36,065                 16,763                 45,838               25,277
                                         ------------------    -------------------     ------------------    -----------------

PROFIT (LOSS) BEFORE
  INCOME TAXES                                    203,050               (187,717)               408,675             (449,561)

Income Tax Provision                               24,100                    ---                 41,200                  ---
                                         ------------------    -------------------     ------------------    -----------------

NET PROFIT (LOSS) AFTER
  INCOME                                       $  178,950           $   (187,717)            $  367,475         $   (449,561)
TAXES
                                         ==================    ===================     ==================    =================


BASIC AND DILUTED EARNINGS (LOSS)
PER SHARE                                         $  0.07              $   (0.07)               $  0.14            $   (0.17)
                                         ==================    ===================     ==================    =================



 See Notes to Financial Statements.
</TABLE>


                                      3
<PAGE>

INFORMEDICS, INC.
BALANCE SHEETS
<TABLE>
<CAPTION>

                                                                             April 30,            October 31,
ASSETS                                                                         1998                   1997
                                                                           ---------------      ---------------
<S>                                                                         <C>                  <C>
CURRENT ASSETS:

Cash                                                                          $  868,758           $  207,692
Accounts Receivable, Less Allowance  for Doubtful
   Accounts of $ 16,200 in 1998 and 1997                                         228,960              445,879
Inventories                                                                       14,848                3,304
Prepaid Expenses and Other Current Assets                                         91,376               55,267
Deferred Income Taxes                                                             59,000               90,500
Current Portion of Long-Term                                                      11,928               11,928
Receivable
                                                                           ---------------      ---------------

Total Current Assets                                                           1,274,870              814,570
                                                                           ---------------      ---------------

FIXED ASSETS:

Furniture and Fixtures                                                           114,171              135,505
Machinery and Equipment                                                          439,205              557,188
Leasehold Improvements                                                            29,583               27,258
Other Fixed Assets                                                               144,004              142,982
                                                                           ---------------      ---------------
                                                                                 726,963              862,933


Less accumulated depreciation and amortization                                   650,560              737,093
                                                                           ---------------      ---------------

Total Fixed Assets                                                                76,403              125,840
                                                                           ---------------      ---------------


OTHER ASSETS:

Long-Term Account Receivable                                                      24,850               30,814
Software Development Costs,
   Less Accumulated  Amortization of $ 825,312
   in 1998 and $ 787,791 in 1997                                                 174,864              169,540
Covenants Not to Compete,
   Less Accumulated Amortization of $ 493,962
   in 1998 and $ 493,862 in 1997                                                      83                  183
Deferred Income Taxes                                                            818,301              932,901
Tax Valuation Allowance                                                         (818,301)            (932,901)
Other                                                                             39,299               39,799
                                                                           ---------------      ---------------


Total Other Assets                                                               239,096              240,336
                                                                           ---------------      ---------------


TOTAL ASSETS                                                                $  1,590,369         $  1,180,746
                                                                           ===============      ===============

See Notes to Financial Statements
</TABLE>

                                      4

<PAGE>

INFORMEDICS, INC.
BALANCE SHEETS


<TABLE>
<CAPTION>

                                                                            April 30,           October 31,
   LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                              1997                1997
                                                                         -----------------    ----------------

<S>                                                                         <C>                  <C>  
   CURRENT LIABILITIES:

   Accounts Payable and Accrued Expenses:
      Trade Accounts                                                          $   63,729           $  87,917
      Customer Deposits                                                           15,810              22,590
      Accrued Wages, Payroll Taxes and Employee Benefits                          65,960              86,362
      Other Accrued Liabilities                                                   15,090               9,445
   Deferred Revenue                                                            1,253,725           1,192,368
   Current Portion of Deferred Rent                                               10,861              13,033
                                                                         -----------------    ----------------

   Total Current Liabilities                                                   1,425,175           1,411,715

   LONG-TERM OBLIGATIONS:

   Deferred Rent                                                                  13,033              17,378
   Deferred Tax Liability                                                         26,400              16,700
                                                                         -----------------    ----------------

   Total Current Liabilities and Long-Term Obligations                         1,464,608           1,445,793
                                                                         -----------------    ----------------

   STOCKHOLDERS' EQUITY (DEFICIT):

   Preferred Stock, $ .01 Par Value:
      Authorized 5,000,000 Shares;
      No Shares Outstanding                                                          ---                 ---
   Common Stock, $.01 Par Value:
      Authorized 15,000,000 Shares;
      Shares Outstanding:  2,674,502 in 1998 and
       2,654,708 in 1997                                                          26,745              26,546
   Capital in Excess of Par Value                                              1,941,176           1,918,042
   Note Receivable from Stockholder                                              (22,000)            (22,000)
   Accumulated Deficit                                                        (1,820,160)         (2,187,635)
                                                                         -----------------    ----------------
                                                                             

   Total Stockholders' Equity (Deficit)                                          125,761            (265,047)
                                                                         -----------------    ----------------


   TOTAL LIABILITIES AND STOCKHOLDERS'
     EQUITY (DEFICIT)                                                       $  1,590,369        $  1,180,746
                                                                         =================   =================




   See Notes to Financial Statements.
</TABLE>

                                      5

<PAGE>


INFORMEDICS, INC.
STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>

                                                                                Six Months Ended April 30,

                                                                       -----------------------------------------
                                                                              1998                   1997
                                                                       -----------------------------------------
<S>                                                                        <C>                  <C>      
CASH FLOWS FROM OPERATING ACTIVITIES:

  Net Income (Loss)                                                          $  367,475           $   (449,561)

ADJUSTMENTS TO RECONCILE NET INCOME
(LOSS) TO NET CASH AND CASH EQUIVALENTS PROVIDED BY (USED IN)
OPERATING ACTIVITIES:
 Depreciation and Amortization                                                   86,254                202,237
 Provision for Write-offs of Accounts Receivable                                    ---                 32,561
 Deferred Income Taxes                                                           41,200                    ---
 Gain on Sale of Assets                                                             ---                 (8,917)
 Changes in Assets and Liabilities:
   Accounts Receivable                                                          216,919                162,308
   Inventories                                                                  (11,544)                 8,957
   Prepaid Expenses and Other Current Assets                                    (36,109)                 4,814
   Accounts Payable and Accrued Expenses                                        (45,725)               (37,701)
   Notes Receivable                                                               5,964                 24,023
   Deferred Revenue                                                              61,357                 14,850
   Deferred Rent                                                                 (6,517)                (6,517)
                                                                       ------------------     ------------------
Net Cash and Cash Equivalents Provided by
   (Used in) Operating Activities                                               679,274                (52,946)
                                                                       ------------------     ------------------

INVESTING ACTIVITIES:
 Property Additions                                                              (6,830)               (23,238)
 Capitalized Software Development Costs                                         (42,844)               (57,823)
 Other                                                                            8,133                  1,942
                                                                       ------------------     ------------------
 Net Cash Used in Investing Activities                                          (41,541)               (79,119)
                                                                       ------------------     ------------------
                                                                                

FINANCING ACTIVITIES:
 Decrease in Revolving Line of Credit                                               ---                (25,000)
 Proceeds from Issuance of Common Stock                                          23,333                    ---
                                                                       ------------------     ------------------

 Net Cash Provided by (Used In) Financing Activities                             23,333                (25,000)
                                                                       ------------------     ------------------

NET INCREASE (DECREASE) IN CASH AND CASH
   EQUIVALENTS                                                                  661,066               (157,065)

CASH AND CASH EQUIVALENTS AT BEGINNING
   OF PERIOD                                                                    207,692                323,217
                                                                       ------------------     ------------------

CASH AND CASH EQUIVALENTS AT END
   OF PERIOD                                                                 $  868,758              $ 166,152
                                                                       ==================     ==================
</TABLE>

                                      6

<PAGE>


 INFORMEDICS, INC.
STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>
                                                                           Six Months Ended April 30,
                                                                   -----------------------------------------
                                                                            1998                  1997
                                                                   -----------------------------------------

<S>                                                                       <C>               <C>
Supplemental Disclosures of Cash Flow
 Information:

Cash paid for:
 Interest                                                                 $  832            $  4,521

                                   





















See Notes to Financial Statements.
</TABLE>

                                      7

<PAGE>


INFORMEDICS, INC.
NOTES  TO FINANCIAL STATEMENTS


1.   SIGNIFICANT ACCOUNTING POLICIES

     Industry Segment
     ----------------

     The  Company  derives its revenue  solely from the sales and  servicing  of
     microcomputer software and related hardware.

     Inventories
     -----------

     Inventories   are  stated  at  the  lower  of  cost  or  market.   Specific
     identification  is used to  determine  the costs of hardware  and  software
     inventory.

     Fixed Assets
     ------------

     Fixed  assets  are  stated  at  cost,  less  accumulated  depreciation  and
     amortization.  The costs of fixed assets are depreciated over the estimated
     useful  lives  (two to five  years) of the assets  using the  straight-line
     method.  Leasehold  improvements  are amortized  over the term of the lease
     (five years).

     Customer Service and Support Revenue
     ------------------------------------

     Customer  service  and  support  revenue  represents  revenue  earned  from
     hardware and software maintenance contracts, training,  installation of new
     systems,  and general software support and programming services provided to
     customers. Under renewable maintenance contracts, the Company provides, for
     a term of generally not more than one year, essentially all maintenance and
     repairs  resulting  from  the  normal  and  intended  use of its  products.
     Deferred revenue on maintenance contracts is amortized by the straight-line
     method over the life of the contracts.

     Revenue Recognition
     -------------------

     Revenue from sales of software and hardware is generally  recorded when the
     product is  shipped.  Revenue  from  custom  software  products,  which are
     marketed to customers  primarily under perpetual license  arrangements,  is
     recorded at the time the product is installed and accepted by the customer.
     Revenue from  services  other than  maintenance  contracts is recognized as
     performed.

     Income Taxes
     ------------

     Income  taxes  are  accounted  for  using the  methodology  established  by
     Statement of Financial  Accounting  Standards ("SFAS") No. 109, "Accounting
     for Income  Taxes,"  which  requires an asset and a  liability  approach to
     financial  accounting and reporting for income taxes.  Deferred  income tax
     assets and liabilities  are computed for differences  between the financial
     statement  and tax  bases of assets  and  liabilities  that will  result in
     taxable or  deductible  amounts in the  future.  A valuation  allowance  is
     established  when  necessary  to reduce  deferred  tax  assets  to  amounts
     expected to be realized,  based on enacted tax laws and rates applicable to
     the periods in which the differences are expected to affect taxable income.
     Income tax  expense or benefit  is the tax  payable or  refundable  for the
     period,  plus or minus the change  during the period in deferred tax assets
     and liabilities.

                                      8

<PAGE>


INFORMEDICS, INC.
NOTES  TO FINANCIAL STATEMENTS


     Software Development Costs
     --------------------------

     Certain software development costs are being capitalized and amortized over
     the estimated  economic life of the software,  on a  straight-line  method,
     commencing  when each  product or  enhancement  is  available  for  general
     release.  Amortization  using the  straight-line  method for the  six-month
     periods  ended  April  30,  1998  and  1997  was $  37,521  and  $  121,040
     respectively.

     Covenants Not to Compete
     ------------------------

     Covenants  not  to  compete  are  stated  at  the  estimated  value  of the
     consideration  given for the covenants  (including the present value of any
     future  payments  to  be  made  under  each  agreement),  less  accumulated
     amortization.  The costs of the covenants are being  amortized over four or
     seven years, using the straight-line method. Amortization for the six-month
     periods ended April 30, 1998 and 1997 was $ 100 and $ 7,718, respectively.

     Earnings Per Share
     ------------------

     In February 1997,  the Financial  Accounting  Standards  Board (the "FASB")
     issued SFAS No. 128,  "Earnings Per Share," which established new standards
     for computing and presenting  earnings per share ("EPS) to entities  having
     publicly  held  common  stock and  potential  common  stock.  SFAS No.  128
     replaces the  presentation  of primary EPS with the dual  presentation of a
     basic EPS and diluted EPS on the Company's  statements of  operations.  The
     Company  computes basic EPS by dividing net income by the  weighted-average
     number of common shares  outstanding and diluted EPS by dividing net income
     by the sum of the weighted-average  number of common shares outstanding and
     the dilutive  effect of stock options and warrants  outstanding  as if such
     options were  exercised  or converted  into common  shares.  The  Company's
     computation  of diluted EPS is essentially  the same as the  computation of
     primary EPS, which was presented prior to the adoption of SFAS No. 128.

     There were no adjustments to net income in computing  diluted  earnings per
     share for the periods  ended April 30, 1998 and 1997.  The Company uses the
     treasury  stock  method to compute the number of shares used in the diluted
     EPS  calculation  and,  as such,  in  1997,  no  shares  are  included  for
     outstanding  stock options as they would be antidilutive.  A reconciliation
     of the  common  shares  used in the  denominator  for  computing  basic and
     diluted EPS for the periods ended April 30, 1998 and 1997 is as follows:
<TABLE>
<CAPTION>

                                         Three Months Ended April 30,       Six Months Ended April 30,
                                         ------------------------------    ------------------------------
                                             1998             1997              1998            1997
                                         -------------    -------------    ------------    --------------
    <S>                                     <C>             <C>             <C>              <C> 

     Weighted-average shares
     outstanding, used in computing
     basic EPS                               2,674,502        2,650,307       2,674,502        2,650,307

     Effect of dilutive stock                   19,900                           19,900
     options                             -------------    -------------    ------------    -------------

     Weighted-average  shares
     outstanding and the effect of
     dilutive stock options used in
     computing diluted EPS                   2,694,402        2,650,307       2,694,402        2,650,307
                                         =============    =============    ============    =============

</TABLE>

                                      9
<PAGE>

INFORMEDICS, INC.
NOTES  TO FINANCIAL STATEMENTS


     Cash and Cash Equivalents
     -------------------------

     The Company considers cash on hand, deposits in bank and highly liquid debt
     instruments  purchased with original  maturity dates of six months or less,
     as cash. 

     Accounting Changes
     ------------------

     In October 1995, the FASB issued SFAS No. 123,  "Accounting for Stock-Based
     Compensation."   This  statement   establishes  an  alternative  method  of
     accounting that requires  recognizing as expense the fair value of employee
     stock options and other stock-based  awards at the grant date. SFAS No. 123
     also allows the  continuation  of the current  accounting  treatment  under
     which the Company  does not  recognize  compensation  expense for the stock
     options it awards to employees. Since the Company is electing to retain its
     current  method,  it is required to present  pro forma  disclosures  in its
     annual  financial  statements  as if the fair value  based  method had been
     applied.

     In June  1997,  the FASB  issued  SFAS No.  130,  "Reporting  Comprehensive
     Income."  SFAS  No.  130   establishes   requirements   for  disclosure  of
     comprehensive  income and becomes  effective for the Company's  fiscal year
     ending October 31, 1999.  Reclassification of earlier financial  statements
     for comparative purposes is required. The impact on the Company's financial
     statements is not material.

     In June 1997, the FASB issued SFAS No. 131,  "Disclosure  about Segments of
     an Enterprise and Related  Information." SFAS No. 131 establishes standards
     for disclosure about operating segments in annual financial  statements and
     selected  information in interim  financial  reports.  It also  establishes
     standards for related  disclosures about products and services,  geographic
     areas,  and  major  customers.  This  statement  supersedes  SFAS  No.  14,
     "Financial  Reporting  for  Segments  of a  Business  Enterprise."  The new
     standard becomes effective for the Company's fiscal year ending October 31,
     1999,  and requires  that  comparative  information  from earlier  years be
     restated to conform to the requirements of this standard.


2.   CREDIT AGREEMENTS

     The Company has no credit line with a bank at this time.

                                      10

<PAGE>


INFORMEDICS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

The following  discussion  includes certain  forward-looking  statements.  Those
statements involve a number of risks and uncertainties, which could cause actual
results  to  differ  materially  from  the  expectation  stated,  including  the
following: slower than expected sales of Informedics' products, deterioration of
business  conditions  generally or  specifically  in the  health-care  industry,
regulatory  changes  involving  health  care  or  medical  devices,  competitive
factors, price pressures and higher than expected turnover in key personnel.

Highlights

On July 29,  1997,  the  Company  signed  a letter  of  intent  to merge  into a
subsidiary of Mediware Systems, Inc.  ("Mediware") of Melville,  NY. The Company
announced on December 19, 1997 the signing of an Agreement and Plan of Merger to
merge into the  Mediware  subsidiary  in a stock  exchange  whereby one share of
Mediware  stock would be exchanged for every 6.3 shares of the Company's  stock.
The merger is subject  to  Securities  and  Exchange  Commission  review and the
approval of the Company's shareholders.

The Company continued  improved operating results for the second quarter and the
first six months of fiscal 1998 when  compared to the same periods in 1997.  The
Company  recorded a pre-tax  profit of $203,050  for the second  quarter of 1998
compared to a second  quarter  loss of $187,717 in 1997 and a pre-tax  profit of
$408,675 for the first six months of 1998 compared to a loss of $449,564 for the
same period in 1997. The  improvement  was primarily the result of  cost-cutting
measures  fully  realized  in fiscal  1998  offset in part by reduced new system
sales.

In  December  1997,  the  Company  received  a  request  from  the Food and Drug
Administration ("FDA") for additional  information and clarifications  regarding
its Section 510(k)  submission for its LifeLine  product.  The FDA requested the
Company  identify  additional  safety critical  functions,  clarify the hardware
platform  on which  its  LifeLine  product  is used,  and  expand  its beta test
information.  Management  believes  that it  adequately  responded  to the FDA's
request on March 26, 1998. If the response  contains  insufficient  information,
the Company's ability to market the LifeLine product may be adversely affected.

The Company is  currently  developing  a new  software  release for the LifeLine
product, which addresses the Year 2000 issue, expanded bar code labeling to meet
anticipated FDA requirements, and customer-recommended  functional improvements.
The Company has evaluated its  anticipated  costs  associated  with this release
(expected in the fourth  quarter of fiscal  1998),  including  staffing  levels,
distribution  costs,  installation  requirements  and  training.  The  Company's
management  believes  that it may incur as much as $300,000 in costs  associated
with this release and other Year 2000 issues.

In 1997, the Company established a valuation reserve against its deferred income
taxes which offset the income tax benefit for the first two quarters of 1997. In
the  third  quarter  of  1997,  this  reserve  was  increased  as the  Company's
management  determined that the benefit of the net operating loss  carryforwards
was not likely to be realized. The Company was able to utilize some of these net
operating loss carryforwards in the second quarter of 1998 to reduce the current
tax provision.

Results of Operations - Material Changes

New system  product  sales were  $228,074  lower in second  quarter and $215,174
lower for the first six  months of 1998 when  compared  to the same  periods  in
1997.  The  decrease  for the six months was due to fewer  sales in all  product
lines,  including  IntraMed.net  - $57,000;  StarPath - $29,765;  and LifeLine -
$11,580.  Discontinued  products  Entree' and  ClinicManager  accounted  for the
remaining product sales shortfall of $116,829.

Customer  service and support  revenue was $6,939  higher in second  quarter and
$47,887  lower for the  first six  months  of 1998,  when  compared  to the same
periods in 1997. The 1997 results included one-time  programming service revenue
associated  with LifeLine and  ClinicManager  product  lines.  Hardware  support
revenue decreased 33% in the first six months of 1998 when compared to the first

                                      11
<PAGE>


six months of 1997,  but the  decline  was more than  offset by a new  technical
support  service  which was  intended to replace the  hardware  support  service
revenue.  The Company began  marketing the new technical  support service in the
second quarter of 1997.

Hardware sales decreased $15,238 and $9,202 for the second quarter and the first
six months of 1998,  respectively,  as compared to the same periods in 1997. The
cost of products  sold in the second  quarter was $10,270 lower and $1,356 lower
in the first six months of 1998 when compared to the same periods in 1997.

The cost of customer service and support decreased $178,747 and $445,558 for the
second  quarter and the first six months of 1998,  respectively,  as compared to
the  same  periods  in  1997.  Likewise,  selling  and  administrative  expenses
decreased in 1998 when  compared to the same  periods in 1997.  These costs were
lower by $323,335 for the second quarter and $532,981 in the first six months of
1998.  The cost  improvements  resulted  from a  reduction  in staff  and  other
overhead costs.  Management  anticipates that these costs will remain relatively
stable over the remainder of fiscal 1998.


Liquidity - Capital Resources

The  Company's  cash position grew from $207,692 on October 31, 1997 to $868,758
on April  30,  1998,  as the  Company  added  $679,274  of cash as a  result  of
operating activities,  used $41,541 for investing activities,  and added $23,333
from  financing  activities.  Based upon the  anticipation  of continued  steady
product  sales and reduced  operating  expenses,  management  believes  that the
Company's  current cash  position  will be  sufficient to fund its operating and
investment activities for the remainder of fiscal 1998.

As a result of the operating profit in the first six months of 1998, the Company
experienced  an improvement  of $446,840 in working  capital.  The Company had a
negative working capital of $150,305 on April 30, 1998 as compared to a negative
$597,145 on October 31, 1997. Excluding the deferred revenue liability, which is
a liability for future services, the Company's working capital on April 30, 1998
was $1,103,420, compared to $595,223 on October 31, 1997.

Capital  expenditures for property additions were $6,830 in the first six months
of 1998  compared  to  $23,238  in the  first  six  months  of 1997.  Management
anticipates that capital  expenditures for property additions for the balance of
1998 will remain low.

Capitalized  software  development  costs were $42,844 and $57,823 for the first
six  months  of  1998  and  1997,  respectively.   Management  anticipates  that
capitalized  software  development  costs for the  remainder of 1998 will remain
low.

The Company has no credit line with a bank at this time.


                                      12
<PAGE>


                        Part II - Other Information




Item 6.   Exhibits and Reports on Form 8-K

               (a)  Exhibit.

                    27  Financial Data Schedule

                (b) Reports on Form 8-K

                    None

                                      13

<PAGE>



                                SIGNATURES



Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                        INFORMEDICS, INC.
                                        (Registrant)


Date  June 12, 1998                     By  /s/ John Tortorici
      --------------                       -------------------------
                                            John Tortorici, Chairman, President,
                                            Chief Executive Officer and
                                            Chief Financial Officer


                                      14


<PAGE>



                                 FORM 10-QSB

                                Exhibit Index

Exhibit
-------

         27    Financial Data Schedule